Alzheimer's disease affects more than 50 million people worldwide, often devastating both the individuals who have it and their families and loved ones.

If at any time during the Second Compliance Period, the closing bid price of the Company’s Ordinary Shares meet or exceed US$1.00 per Ordinary Share for at least ten consecutive business days, Nasdaq ...

Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in 2026 -- VY1706 is the ...